UPDATE: Deutsche Bank Raises PT on Aegerion Pharmaceuticals on Strong Juxtapid Uptake
In a report published Wednesday, Deutsche Bank reiterated its Buy rating on Aegerion Pharmaceuticals (NASDAQ: AEGR), and raised its price target from $37.00 to $41.00.
Deutsche Bank noted, “We also have higher conviction in peds-HOFH OPP'Y. However, we are removing FC OPP'Y from numbers on limited progress so far...Given that patient uptake has robust so far, we believe there could be upside to 2013 company guidance of $15-$25M in sales. We calculate that the company can generate $13M sales in 2013 with only these 85 pts added so far.”
Aegerion Pharmaceuticals closed on Tuesday at $34.47.
Latest Ratings for AEGR
|Feb 2016||Bank of America||Downgrades||Neutral||Underperform|
|Nov 2015||Bank of America||Upgrades||Underperform||Neutral|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.